Lung Cancer Screening Expansion Act of 2025
- Bill Number
- H.R. 6314
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-10: Referred to the Subcommittee on Health.
- Last Updated
- 2026-04-24T20:42:03Z
AI-Generated Summary
Purpose
The Lung Cancer Screening Expansion Act of 2025 aims to improve early detection of lung cancer by mandating insurance coverage for annual screenings among adults aged 50 to 80 who are at increased risk, without additional costs to patients. This promotes preventive health measures to reduce lung cancer mortality through accessible, evidence-based screening.
Key Provisions
- Coverage Mandate: All health insurers, including group health plans, individual health insurance providers, and federal health programs (like Medicare and Medicaid), must fully cover annual low-dose computed tomography (LDCT) scans or other suitable lung cancer screening methods. LDCT is a low-radiation CT scan used to detect lung abnormalities early.
- No Cost-Sharing: Coverage must be provided without patient out-of-pocket costs, such as deductibles, copays, or coinsurance.
- Prohibited Barriers:
- No requirements for prior authorization (pre-approval from the insurer).
- No step-therapy (trying other treatments first) or other utilization controls.
- No limits on frequency stricter than one screening per year.
- No extra documentation beyond standard evidence-based clinical guidelines (recommendations from medical experts based on research).
- Eligibility Criteria: Applies to adults aged 50 to 80 who are assessed by a healthcare professional as being at increased risk due to personal factors (e.g., smoking history), environmental exposures (e.g., radon or pollution), or family history of lung cancer.
- Implementation: The Secretary of Health and Human Services (HHS), Secretary of Defense, Secretary of Veterans Affairs, and Director of the Office of Personnel Management (OPM) must issue regulations within 180 days of enactment to ensure compliance across federal programs.
Significant Changes to Existing Law
- Builds on the Affordable Care Act (ACA), which already requires no-cost coverage for certain preventive services, but expands it specifically for lung cancer screening by making annual screenings mandatory for a broader risk-based group (beyond just heavy smokers, as in current guidelines).
- Introduces stricter prohibitions on administrative barriers, potentially simplifying access compared to varying state or insurer policies.
- Applies uniformly to federal health programs, ensuring consistency across military, veterans', and federal employee benefits, which may not have had such comprehensive mandates before.
Potential Impacts
- On Citizens: Increases access to free annual screenings for millions of at-risk adults, potentially leading to earlier diagnoses, better treatment outcomes, and reduced lung cancer deaths. It removes financial and bureaucratic hurdles, benefiting underserved populations with environmental or familial risks.
- On Government Agencies: HHS, Department of Defense (DoD), Department of Veterans Affairs (VA), and OPM must update programs like TRICARE (military health) and FEHB (federal employee health benefits), increasing short-term administrative costs but possibly yielding long-term savings through preventive care.
- On Health Insurers: Requires adjustments to coverage policies, which could raise premiums slightly but encourage preventive health to lower overall treatment expenses.
- International Relations: No direct impact, as this is a domestic health policy focused on U.S. insurance and federal programs.
Main Stakeholders Affected
- Eligible Individuals: Adults aged 50-80 at increased lung cancer risk, including current/former smokers, those with occupational exposures, or family history.
- Healthcare Providers: Doctors and clinics that assess risk and order screenings, gaining clearer guidelines for recommending tests.
- Health Insurers and Plans: Private insurers, group plans, and federal programs responsible for covering costs without barriers.
- Federal Agencies: HHS (overseeing Medicare/Medicaid), DoD (military health), VA (veterans' care), and OPM (federal employees), tasked with enforcement and regulation.
- Public Health Organizations: Groups like the American Cancer Society, which may support expanded screenings aligned with their guidelines.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens preventive care mandates under the ACA without conflicting with it, potentially reducing litigation over coverage denials by standardizing requirements. Evidence-based guidelines provide a defensible basis to avoid challenges on medical necessity.
- Constitutional: No apparent issues, as it involves federal regulation of interstate commerce (health insurance) and spending on public health, consistent with Congress's authority.
- Political: Advances bipartisan public health priorities by addressing a leading cancer killer, but could spark debates on federal overreach into insurance or costs to taxpayers/insurers. It promotes equity in healthcare access, aligning with efforts to reduce disparities in underserved communities.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Rep. Torres, Ritchie [D-NY-15]
Recent Actions
- 2025-12-10: Referred to the Subcommittee on Health.
- 2025-11-25: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Oversight and Government Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-11-25: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Oversight and Government Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-11-25: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Oversight and Government Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-11-25: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Oversight and Government Reform, and Veterans' Affairs, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2025-11-25: Introduced in House
- 2025-11-25: Introduced in House
Bill Versions
- Lung Cancer Screening Expansion Act of 2025 — issued 2025-11-25 — PDF (3 pages)